Clinical Trials
12 trialsNCT02924272 2025-03-12
Ixazomib Rollover Study
Takeda
Phase 2 Completed
NCT03959358 2023-07-24
A Study to Desensitize Allergic Reactions to Treatments for Blood Disorders
University Health Network, Toronto
Phase 2 Completed
NCT00224393 2023-05-30
Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis
The Cleveland Clinic
Phase 2 Completed
NCT02207556 2021-07-09
DUAL
Medical College of Wisconsin
Phase 2 Completed
NCT01083316 2020-09-25
Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis
Boston Medical Center
Phase 2 Completed
NCT01222260 2020-03-30
Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis
Columbia University
Phase 2 Completed
NCT01447914 2019-08-28
Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Completed
NCT02632786 2019-04-05
PRONTO
Prothena Biosciences Ltd.
Phase 2 Completed
NCT02791373 2018-04-03
ViGeM
Insel Gruppe AG, University Hospital Bern
Phase 2 Completed
NCT01677286 2017-08-01
Safety and Effect of Doxycycline in Patients With Amyloidosis
Boston University
Phase 2 Completed
NCT01194791 2017-04-25
LENDEXAL
PETHEMA Foundation
Phase 2 Completed
NCT00017680 2008-06-09
Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis
Office of Rare Diseases (ORD)
Phase 2 Completed